Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?

Pan-African Studies to Evaluate Resistance

doi:https://doi.org/10.1093/cid/ciy1070

Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?

Pan-African Studies to Evaluate Resistance

Research output: Contribution to journal › Letter › Academic › peer-review

3 Citations (Scopus)

Original language	English
Article number	ciy1070
Pages (from-to)	2158-2160
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	68
Issue number	12
DOIs	https://doi.org/10.1093/cid/ciy1070
Publication status	Published - 2019

Access to Document

https://doi.org/10.1093/cid/ciy1070

Cite this

@article{ffa77253f2164a3cb02494396b8ead5f,

title = "Does Tenofovir-containing First-line Antiretroviral Therapy Mitigate the Impact of Pretreatment Non-nucleoside Reverse Transcriptase Inhibitor Drug Resistance?",

author = "{Pan-African Studies to Evaluate Resistance} and Inzaule, {Seth C.} and {Rinke de Wit}, {Tobias F.} and Hamers, {Raph L.}",

year = "2019",

doi = "https://doi.org/10.1093/cid/ciy1070",

language = "English",

volume = "68",

pages = "2158--2160",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",